Related Experiment Video
Updated: May 15, 2025
Parallel High Throughput Single Molecule Kinetic Assay for Site-Specific DNA Cleavage
Published on: May 6, 2020
A novel platform for precise senolysis
Anastasia Conti1, Raffaella Di Micco2
1San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Milan 20132, Italy.
A new senolytic platform, mGL392, selectively eliminates senescent cells to treat aging and cancer. This advanced drug delivery system reduces systemic toxicity and off-target effects, offering a safer therapeutic approach.
Area of Science:
- Biomedical research
- Drug discovery
- Aging and cancer therapeutics
Background:
- Senescent cells contribute to aging and cancer.
- Current senolytic drugs can cause systemic toxicity and off-target effects.
Purpose of the Study:
- To introduce mGL392, an advanced senolytic platform.
- To evaluate the efficacy and safety of mGL392 in eliminating senescent cells.
Main Methods:
- Development of mGL392 using a lipofuscin-binding domain scaffold conjugated with a senolytic drug (dasatinib).
- In vitro and in vivo testing of mGL392 for senescent cell elimination.
- Assessment of tumor size reduction in melanoma models and systemic toxicity.
Main Results:
- mGL392 effectively eliminated senescent cells in vitro and in vivo.
- Reduced tumor size in melanoma models.
- Minimized systemic toxicity compared to existing senolytics.
- Demonstrated improved specificity and reduced off-target effects.
Conclusions:
- mGL392 represents a safer and more effective senolytic platform.
- This innovation holds promise for treating senescence-associated diseases like aging and cancer.
More Related Videos
11:53Predicting Gene Silencing Through the Spatiotemporal Control of siRNA Release from Photo-responsive Polymeric Nanocarriers
Published on: July 21, 2017
16:02Quantitative FRET Förster Resonance Energy Transfer Analysis for SENP1 Protease Kinetics Determination
Published on: February 21, 2013